Description: Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Home Page: www.celldex.com
Perryville III Building
Hampton,
NJ
08827
United States
Phone:
908 200 7500
Officers
| Name | Title |
|---|---|
| Mr. Anthony S. Marucci M.B.A. | Founder, President, CEO & Director |
| Dr. Tibor Keler Ph.D. | Founder, Chief Scientific Officer & Executive VP |
| Mr. Sam Martin CPA | Senior VP, CFO, Secretary & Treasurer |
| Dr. Margo Heath-Chiozzi M.D. | Senior Vice President of Regulatory Affairs |
| Dr. Diane C. Young M.D. | Senior VP & Chief Medical Officer |
| Prof. Joseph P. Schlessinger Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Ms. Sarah Cavanaugh | Senior Vice President of Corporate Affairs & Administration |
| Mr. Freddy A. Jimenez Esq. | Senior VP & General Counsel |
| Dr. Ronald A. Pepin | Chief Business Officer & Senior VP |
| Ms. Elizabeth Crowley | Chief Product Development Officer & Senior VP |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1804 |
| Price-to-Sales TTM: | 164.8671 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 160 |